Tirzepatide hits two receptors and retatrutide hits three, and neither is a gimmick. Here's how agonism, antagonism, and biased signaling actually work at the receptor level, and why combining several of them in one peptide became the dominant strategy in metabolic drug design.
Gpcr
-
Multi-Receptor Peptide Design: One Molecule, Several Targets